Last 12 months
Inside the activity.
45 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 10 | 0 |
| Apr 2026 | 15 | 0 |
| May 2026 | 10 | 0 |
| Jun 2026 | 9 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2024 Filed Aug 2, 2024 21:34 UTC |
Bigora SianChief Development Officer
|
GrantRestricted Stock Units · Derivative | 2,425 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · derivative · entry 7 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,153 Underlying: Common Stock · 2,425 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:34 UTC |
Bigora SianChief Development Officer
|
GrantRestricted Stock Units · Derivative | 3,233 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · derivative · entry 6 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,728 Underlying: Common Stock · 3,233 shares Expires not disclosed F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 17:31 UTC |
Stanker James HChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 385 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · derivative · entry 8 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,547 Underlying: Common Stock · 385 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 17:31 UTC |
Stanker James HChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 385 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · derivative · entry 7 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,162 Underlying: Common Stock · 385 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 17:31 UTC |
Stanker James HChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 2,307 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · derivative · entry 6 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,777 Underlying: Common Stock · 2,307 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 17:31 UTC |
Stanker James HChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 3,077 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · derivative · entry 5 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,470 Underlying: Common Stock · 3,077 shares Expires not disclosed F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:09 UTC |
Young DavidDirector · Pres. Research & Development
|
GrantRestricted Stock Units · Derivative | 404 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · derivative · entry 11 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,155 Underlying: Common Stock · 404 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:09 UTC |
Young DavidDirector · Pres. Research & Development
|
GrantRestricted Stock Units · Derivative | 404 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · derivative · entry 10 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,751 Underlying: Common Stock · 404 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:09 UTC |
Young DavidDirector · Pres. Research & Development
|
GrantRestricted Stock Units · Derivative | 2,425 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · derivative · entry 9 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,347 Underlying: Common Stock · 2,425 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:09 UTC |
Young DavidDirector · Pres. Research & Development
|
GrantRestricted Stock Units · Derivative | 3,233 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · derivative · entry 8 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,922 Underlying: Common Stock · 3,233 shares Expires not disclosed F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right receive one share of the Issuer's common stock, following its vesting on January 1, 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right receive one share of the Issuer's common stock, following its vesting on January 1, 2025. Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:12 UTC |
Guy WendyChief Administrative Officer
|
Tax withholdingCommon Stock | 368 | $2.79 | $1,026.72 |
DisclosureSEC source: 0000897069-24-001608 · form4.xml · nonDerivative · entry 2 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,433 Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:12 UTC |
Guy WendyChief Administrative Officer
|
Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001608 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:28 UTC |
Lin PatrickChief Business - Strategy Off
|
Tax withholdingCommon Stock | 539 | $2.79 | $1,503.81 |
DisclosureSEC source: 0000897069-24-001611 · form4.xml · nonDerivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,686 Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:28 UTC |
Lin PatrickChief Business - Strategy Off
|
Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001611 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:34 UTC |
Bigora SianChief Development Officer
|
Tax withholdingCommon Stock | 368 | $2.79 | $1,026.72 |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · nonDerivative · entry 2 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,459 Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:34 UTC |
Bigora SianChief Development Officer
|
Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001615 · form4.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 17:31 UTC |
Stanker James HChief Financial Officer
|
Tax withholdingCommon Stock | 518 | $2.79 | $1,445.22 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · nonDerivative · entry 2 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,120 Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 17:31 UTC |
Stanker James HChief Financial Officer
|
Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:09 UTC |
Young DavidDirector · Pres. Research & Development
|
Tax withholdingCommon Stock | 518 | $2.79 | $1,445.22 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · nonDerivative · entry 2 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,543 Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:09 UTC |
Young DavidDirector · Pres. Research & Development
|
Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:30 UTC |
Young DavidDirector · Pres. Research & Development
|
PurchaseCommon Stock | 21,000 | $2.45 | $51,525.60 |
DisclosureSEC source: 0000897069-24-000269 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,387 Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:22 UTC |
Young DavidDirector · Pres. Research & Development
|
PurchaseCommon Stock | 20,000 | $2.53 | $50,504.00 |
DisclosureSEC source: 0000897069-24-000253 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,387 F1 · ownership.direct: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| February 01, 2024 Filed Feb 1, 2024 23:32 UTC |
Lin PatrickChief Business - Strategy Off
|
PurchaseCommon Stock | 1,500 | $2.40 | $3,600.00 |
DisclosureSEC source: 0000897069-24-000236 · form4.xml · nonDerivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,478 F1 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:32 UTC |
Lin PatrickChief Business - Strategy Off
|
PurchaseCommon Stock | 2,500 | $2.37 | $5,925.00 |
DisclosureSEC source: 0000897069-24-000236 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,978 F1 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:37 UTC |
Ng George KDirector · Chief Executive Officer
|
PurchaseCommon Stock | 10,000 | $2.70 | $27,000.00 |
DisclosureSEC source: 0000897069-24-000229 · form4.xml · nonDerivative · entry 1 Ng George K · CIK 0001638744 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 20,000 F1 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Reflects that shares previously reported as directly held by the reporting person were held in a trust. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:34 UTC |
Yorke Justin WDirector
|
PurchaseCommon Stock | 8,000 | $2.69 | $21,544.00 |
DisclosureSEC source: 0000897069-24-000227 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Richland Fund, LLC Disclosed balance after: 31,232 F1 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:50 UTC |
Guy WendyChief Administrative Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000917 · form4.xml · derivative · entry 4 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,132 Underlying: Common Stock · 1,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:50 UTC |
Guy WendyChief Administrative Officer
|
Tax withholdingCommon Stock | 368 | $2.79 | $1,026.72 |
DisclosureSEC source: 0000897069-24-000917 · form4.xml · nonDerivative · entry 2 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,433 F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:50 UTC |
Guy WendyChief Administrative Officer
|
Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-000917 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:55 UTC |
Lin PatrickChief Business - Strategy Off
|
Exercise / conversionRestricted Stock Units · Derivative | 1,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000921 · form4.xml · derivative · entry 3 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,132 Underlying: Common Stock · 1,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:55 UTC |
Lin PatrickChief Business - Strategy Off
|
Tax withholdingCommon Stock | 539 | $2.79 | $1,503.81 |
DisclosureSEC source: 0000897069-24-000921 · form4.xml · nonDerivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,614 F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:55 UTC |
Lin PatrickChief Business - Strategy Off
|
Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-000921 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:52 UTC |
Bigora SianChief Development Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000919 · form4.xml · derivative · entry 4 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,139 Underlying: Common Stock · 1,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:52 UTC |
Bigora SianChief Development Officer
|
Tax withholdingCommon Stock | 368 | $2.79 | $1,026.72 |
DisclosureSEC source: 0000897069-24-000919 · form4.xml · nonDerivative · entry 2 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,458 F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:52 UTC |
Bigora SianChief Development Officer
|
Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-000919 · form4.xml · nonDerivative · entry 1 Bigora Sian · CIK 0001799365 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 16:57 UTC |
Stanker James HChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000923 · form4.xml · derivative · entry 3 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,037 Underlying: Common Stock · 1,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 16:57 UTC |
Stanker James HChief Financial Officer
|
Tax withholdingCommon Stock | 518 | $2.79 | $1,445.22 |
DisclosureSEC source: 0000897069-24-000923 · form4.xml · nonDerivative · entry 2 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,120 F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 16:57 UTC |
Stanker James HChief Financial Officer
|
Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-000923 · form4.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 21:01 UTC |
Young DavidDirector · Pres. Research & Development
|
Exercise / conversionRestricted Stock Units · Derivative | 1,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000925 · form4.xml · derivative · entry 6 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,333 Underlying: Common Stock · 1,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 21:01 UTC |
Young DavidDirector · Pres. Research & Development
|
Tax withholdingCommon Stock | 518 | $2.79 | $1,445.22 |
DisclosureSEC source: 0000897069-24-000925 · form4.xml · nonDerivative · entry 2 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,544 F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 21:01 UTC |
Young DavidDirector · Pres. Research & Development
|
Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-000925 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| November 21, 2023 Filed Nov 28, 2023 21:13 UTC |
Yorke Justin WDirector
|
OtherCommon Stock | 55,267 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-23-001674 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Richland Fund, LLC Disclosed balance after: 464,623 F1 · kind: Represents a transfer of shares to a fund that the Reporting Person does not manage. As a result, the reporting person is no longer deemed to be the beneficial owner of such shares. Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 22:07 UTC |
Guy WendyChief Administrative Officer
|
GrantCommon Stock | 14,771 | $0.34 | $5,022.14 |
DisclosureSEC source: 0000897069-23-001470 · form4.xml · nonDerivative · entry 1 Guy Wendy · CIK 0001799360 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,517 Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 22:01 UTC |
Lin PatrickChief Business - Strategy Off
|
GrantCommon Stock | 5,000 | $0.32 | $1,600.00 |
DisclosureSEC source: 0000897069-23-001466 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,535 Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 17:58 UTC |
Stanker James HChief Financial Officer
|
GrantCommon Stock | 15,000 | $0.33 | $4,950.00 |
DisclosureSEC source: 0000897069-23-001464 · form4.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,250 Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 22:04 UTC |
Ng George KDirector · Chief Executive Officer
|
GrantCommon Stock | 100,000 | $0.25 | $25,000.00 |
DisclosureSEC source: 0000897069-23-001468 · form4.xml · nonDerivative · entry 1 Ng George K · CIK 0001638744 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 21:56 UTC |
Yorke Justin WDirector
|
GrantCommon Stock | 6,000 | $0.30 | $1,800.00 |
DisclosureSEC source: 0000897069-23-001462 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,729 Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 21:54 UTC |
Young DavidDirector · Pres. Research & Development · 10% owner
|
GrantCommon Stock | 155,277 | $0.29 | $45,030.33 |
DisclosureSEC source: 0000897069-23-001460 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 767,701 Read SEC document |
| October 12, 2023 Filed Oct 23, 2023 21:31 UTC Amendment |
Yorke Justin WDirector
|
GrantCommon Stock | 6,000 | $0.30 | $1,800.00 |
DisclosureSEC source: 0000897069-23-001499 · form4.xml · nonDerivative · entry 1 Yorke Justin W · CIK 0001361896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,729 F1 · balance_after: Amendment filed solely to correct the amount directly owned reported on the Form 4 filed October 12, 2023 and the Form 4 filed on October 10/10/2023. Read SEC document |
| October 10, 2023 Filed Oct 10, 2023 21:05 UTC |
Pannu GeraldineDirector
|
GrantCommon Stock | 4,500 | $0.21 | $945.00 |
DisclosureSEC source: 0000897069-23-001446 · form4.xml · nonDerivative · entry 1 Pannu Geraldine · CIK 0001817209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,613 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.